Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IDIA.SW
- Price
- 1.90
- Stock movement down
- -0.03 (-1.55%)
- Company name
- Idorsia Ltd
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Biotechnology
- Market cap
- 357.82M
- Ent value
- 1.66B
- Price/Sales
- 5.07
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -11.37%
- 1 year return
- -4.52%
- 3 year return
- -47.15%
- 5 year return
- -42.47%
- 10 year return
- -
Last updated: 2025-06-22
DIVIDENDS
IDIA.SW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.07 |
| Price to Book | - |
| EV to Sales | 23.55 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 188.33M |
| EPS (TTM) | -1.57 |
| FCF per share (TTM) | -2.35 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 70.62M |
| Gross profit (TTM) | 38.78M |
| Operating income (TTM) | -385.38M |
| Net income (TTM) | -296.39M |
| EPS (TTM) | -1.57 |
| EPS (1y forward) | -0.17 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 54.92% |
| Operating margin (TTM) | -545.69% |
| Profit margin (TTM) | -419.68% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 77.30M |
| Net receivables | 23.09M |
| Total current assets | 198.89M |
| Goodwill | 0.00 |
| Intangible assets | 13.60M |
| Property, plant and equipment | 0.00 |
| Total assets | 432.60M |
| Accounts payable | 13.32M |
| Short/Current long term debt | 1.26B |
| Total current liabilities | 317.14M |
| Total liabilities | 1.38B |
| Shareholder's equity | -949.93M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -427.18M |
| Capital expenditures (TTM) | 18.16M |
| Free cash flow (TTM) | -445.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -68.51% |
| Return on Invested Capital | 39.52% |
| Cash Return on Invested Capital | 59.38% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.93 |
| Daily high | 2.04 |
| Daily low | 1.90 |
| Daily Volume | 1.80M |
| All-time high | 33.62 |
| 1y analyst estimate | 1.53 |
| Beta | 1.29 |
| EPS (TTM) | -1.57 |
| Dividend per share | - |
| Ex-div date | 16 Jun 2017 |
| Next earnings date | 30 Jul 2025 |
Downside potential
Loading...
Downside potential data
| IDIA.SW | S&P500 | |
| Current price drop from All-time high | -94.35% | -3.04% |
| Highest price drop | -98.12% | -56.47% |
| Date of highest drop | 20 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -47.07% | -11.04% |
| Avg time to new high | 54 days | 12 days |
| Max time to new high | 1362 days | 1805 days |
COMPANY DETAILS
Marketcap
357.82M
Marketcap category
Small-cap
Description
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia. The company has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and commercialize PIVLAZ. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Key Insights Idorsia's significant retail investors ownership suggests that the key decisions are influenced by...
July 6, 2025
Ad hoc announcement pursuant to Art. 53 LR Potential first-ever vaccine directed against C. difficile bacteria and spores induces positive antigen titers in humans that recognize the bacteriaInitial d...
June 30, 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025Idorsia Ltd. (SIX: IDIA) today announced the positive outcome of two bondholder meetings held at 17:30 CEST and 19:00 C...
June 25, 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200 mi...
June 25, 2025
Ad hoc announcement pursuant to Art. 53 LR Idorsia to receive USD 50 million (an additional USD 30 million) approval milestone payment in return for a reduction in Simcere potential sales milestones a...
June 23, 2025
Ad hoc announcement pursuant to Art. 53 LR André C. Muller, current CEO of Idorsia, to retire and act as an advisor to the company to ensure a smooth transition Allschwil, Switzerland – June 10, 2025I...
June 10, 2025
Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the terms of the two outstanding convertible bonds CB 2025 and...
June 6, 2025
Allschwil, Switzerland – May 28, 2025At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Boa...
May 28, 2025
Ad hoc announcement pursuant to Art. 53 LR CHF 150 million new money facility from bondholders now implemented and providing cash runway to mid-2026Holistic convertible debt restructuring progressing ...
May 21, 2025
Allschwil, Switzerland – May 2, 2025Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to...
May 2, 2025
Next page